Quantifying the Contribution of Symptom Improvement to Satisfaction of Men With Moderate to Severe Benign Prostatic Hyperplasia: 4-Year Data From the CombAT Trial
Abstract
Purpose:
We quantified the magnitude of symptom improvement required to achieve different levels of patient reported satisfaction, as assessed by the Patient Perception of Study Medication questionnaire.
Materials and Methods:
This multicenter, international, double-blind, randomized study included men 50 years old or older with International Prostate Symptom Score 12 or greater, prostate volume 30 cc or greater, total prostate specific antigen 1.5 to 10.0 ng/ml, maximum urinary flow greater than 5 and less than or equal to 15 ml per second and minimum voided volume 125 ml or greater. Patients were randomized to dutasteride (0.5 mg) and/or tamsulosin (0.4 mg) but results are reported without respect to treatment. International Prostate Symptom Score and Patient Perception of Study Medication responses were assessed at baseline and at 3-month intervals for 48 months. Using pooled data Patient Perception of Study Medication responses were correlated with changes in International Prostate Symptom Score from baseline for 2 Patient Perception of Study Medication measures, including 1) total score and 2) overall satisfaction on question 11, “Overall how satisfied are you with the study medication and its effect on your urinary problems?”
Results:
Patient Perception of Study Medication total score and question 11 correlated significantly with the mean change in International Prostate Symptom Score from baseline (p <0.0001). A response of very satisfied to question 11 was associated with an International Prostate Symptom Score improvement of −9.4 points while a response of very dissatisfied was associated with 1.3-point worsening. There was only moderate correlation between Patient Perception of Study Medication question 11 and changes in symptoms (r = 0.38). Thus, factors other than lower urinary tract symptoms also contribute to satisfaction and they could not be formally analyzed in this report.
Conclusions:
We noted correlations between patient satisfaction and the magnitude of the International Prostate Symptom Score change from baseline, which allowed us to determine treatment outcomes in terms of true clinical instead of only statistical significance.
References
- 1 AUA guideline on management of benign prostatic hyperplasia: (2003): Chapter 1: diagnosis and treatment recommendations. J Urol2003; 170: 530. Link, Google Scholar
- 2 : EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol2004; 46: 547. Google Scholar
- 3 : Eliciting preferences for drug treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol2004; 172: 2321. Link, Google Scholar
- 4 : The importance of patient perception in the clinical assessment of benign prostatic hyperplasia and its management. BJU Int2005; 95: 15. Google Scholar
- 5 : The psychometric validation of a US English satisfaction measure for patients with benign prostatic hyperplasia and lower urinary track symptoms. Health Qual Life Outcomes2009; 7: 55. Google Scholar
- 6 : Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design. Contemp Clin Trials2007; 28: 770. Google Scholar
- 7 : The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol2010; 57: 123. Google Scholar
- 8 : Linguistic Validation Manual for Patient Reported Outcomes (PRO) Instruments. Lyon: MAPI Research Trust2004. Google Scholar
- 9 Food and Drug Administration Guidance for Industry: Patient Reported Outcome Measures: Use in Medicinal Product Development to Support Labeling Claims (Draft Guidance): Department of Health and Human Services, Food and Drug Administration 2006. http://www.fda.gov/CDER/GUIDANCE/5460dft.pdf. Accessed November 7, 2011.. Google Scholar
- 10 : Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?. J Urol1995; 154: 1770. Link, Google Scholar
- 11 : Effect of dutasteride, tamsulosin and the combination on patient reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial. BJU Int2009; 103: 919. Google Scholar
- 12 : The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med2003; 349: 2387. Google Scholar
